Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | PICK-NEPC: avelumab in NEPC/AVPC

Andrew Armstrong, MD, Duke Cancer Institute, Durham, NC, outlines the efficacy results of the Phase II single-arm PICK-NEPC study (NCT03179410) of the PD-L1 inhibitor, avelumab, in patients with neuroendocrine or aggressive variant prostate cancer (NEPC/AVPC). The overall response rate (ORR) was 6.7% with one complete response in a patient who had NEPC with a CNS metastasis that was microsatellite instability (MSI)-high. Three patients achieved stable disease but 11 had progressive disease. PD-L1 inhibition with avelumab exhibited limited clinical efficacy in men with metastatic NEPC/AVPC. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Andrew Armstrong, MD, has received consulting and research support from Pfizer, Merck, Astellas, Janssen, Genentech/Roche, AstraZeneca, BMS and Dendreon.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.